Datopotamab Deruxtecan (Dato-DXd) Global Commercial Breast Cancer Steering Committee Meeting
Premeeting Survey

Dear Steering Committee Member,

The Daiichi Sankyo/AstraZeneca Global Commercial team is looking forward to working with you at the upcoming Datopotamab Deruxtecan (Dato-DXd) Global Commercial Breast Cancer Steering Committee Meeting on Thursday, December 7, 2023, from 7:00 pm-10:00 pm (CST), in San Antonio, Texas.

To prepare for the meeting discussions, please complete this brief survey by Tuesday, November 28, 2023. Responses will be collated and will provide baseline information to help finalize our meeting content. Your individual responses will remain anonymous.

Question Title

* Please enter the following information as you would like noted on the meeting materials:

First Name:

Last Name:

Degree(s):

Title:

Institution or Practice Name:

Institution or Practice City, Country:

Please provide a mobile number we can use to contact you on the day of the meeting:

Question Title

* 1. Results from TROPION-Breast01, a Phase 3 study of datopotamab deruxtecan (Dato-DXd) vs standard chemotherapy for 2-3L post–endocrine therapy (ET) HR+/HER2− mBC, were recently presented at ESMO 2023. In thinking of the efficacy endpoints individually, please rate how impactful you find each of the following efficacy results using a scale of 1 to 5, where 1=not at all impactful and 5=very impactful.

	1 = not at all impactful	2	3	4	5 = very impactful
Median PFS	Median PFS 1 = not at all impactful	Median PFS 2	Median PFS 3	Median PFS 4	Median PFS 5 = very impactful
Kaplan-Meier curves for PFS	Kaplan-Meier curves for PFS 1 = not at all impactful	Kaplan-Meier curves for PFS 2	Kaplan-Meier curves for PFS 3	Kaplan-Meier curves for PFS 4	Kaplan-Meier curves for PFS 5 = very impactful
Landmark PFS rate at 9 mo	Landmark PFS rate at 9 mo 1 = not at all impactful	Landmark PFS rate at 9 mo 2	Landmark PFS rate at 9 mo 3	Landmark PFS rate at 9 mo 4	Landmark PFS rate at 9 mo 5 = very impactful
PFS HR	PFS HR 1 = not at all impactful	PFS HR 2	PFS HR 3	PFS HR 4	PFS HR 5 = very impactful
PFS subgroup analysis	PFS subgroup analysis 1 = not at all impactful	PFS subgroup analysis 2	PFS subgroup analysis 3	PFS subgroup analysis 4	PFS subgroup analysis 5 = very impactful
ORR	ORR 1 = not at all impactful	ORR 2	ORR 3	ORR 4	ORR 5 = very impactful
OS HR (not yet mature)	OS HR (not yet mature) 1 = not at all impactful	OS HR (not yet mature) 2	OS HR (not yet mature) 3	OS HR (not yet mature) 4	OS HR (not yet mature) 5 = very impactful

Other (please specify)

Question Title

* 2. Please think of the efficacy endpoints from TROPION-Breast01 collectively and rank in order of impact, where 1=least impactful and 8=most impactful.

	1=not at all impactful	2	3	4	5	6	7	8=most impactful
Median PFS	Median PFS 1=not at all impactful	Median PFS 2	Median PFS 3	Median PFS 4	Median PFS 5	Median PFS 6	Median PFS 7	Median PFS 8=most impactful
Kaplan-Meier curves for PFS	Kaplan-Meier curves for PFS 1=not at all impactful	Kaplan-Meier curves for PFS 2	Kaplan-Meier curves for PFS 3	Kaplan-Meier curves for PFS 4	Kaplan-Meier curves for PFS 5	Kaplan-Meier curves for PFS 6	Kaplan-Meier curves for PFS 7	Kaplan-Meier curves for PFS 8=most impactful
Landmark PFS rate at 9 mo	Landmark PFS rate at 9 mo 1=not at all impactful	Landmark PFS rate at 9 mo 2	Landmark PFS rate at 9 mo 3	Landmark PFS rate at 9 mo 4	Landmark PFS rate at 9 mo 5	Landmark PFS rate at 9 mo 6	Landmark PFS rate at 9 mo 7	Landmark PFS rate at 9 mo 8=most impactful
PFS HR	PFS HR 1=not at all impactful	PFS HR 2	PFS HR 3	PFS HR 4	PFS HR 5	PFS HR 6	PFS HR 7	PFS HR 8=most impactful
PFS subgroup analysis	PFS subgroup analysis 1=not at all impactful	PFS subgroup analysis 2	PFS subgroup analysis 3	PFS subgroup analysis 4	PFS subgroup analysis 5	PFS subgroup analysis 6	PFS subgroup analysis 7	PFS subgroup analysis 8=most impactful
ORR	ORR 1=not at all impactful	ORR 2	ORR 3	ORR 4	ORR 5	ORR 6	ORR 7	ORR 8=most impactful
OS HR (not yet mature)	OS HR (not yet mature) 1=not at all impactful	OS HR (not yet mature) 2	OS HR (not yet mature) 3	OS HR (not yet mature) 4	OS HR (not yet mature) 5	OS HR (not yet mature) 6	OS HR (not yet mature) 7	OS HR (not yet mature) 8=most impactful
Other (please specify below)	Other (please specify below) 1=not at all impactful	Other (please specify below) 2	Other (please specify below) 3	Other (please specify below) 4	Other (please specify below) 5	Other (please specify below) 6	Other (please specify below) 7	Other (please specify below) 8=most impactful

Other (please specify)

Question Title

* 3. Please explain the rationale behind your top 3 choices for the most impactful efficacy data from TROPION-Breast01 in the prior question.

Question Title

* 4. For the safety data from TROPION-Breast01, please think of the following safety results individually and rate how well each result differentiates Dato-DXd in the HR+/HER2− mBC landscape, using a scale of 1 to 5, where 1=not at all differentiating and 5=very differentiating.

	1=not at all differentiating	2	3	4	5=very differentiating
Grade ≥3 AEs rates	Grade ≥3 AEs rates 1=not at all differentiating	Grade ≥3 AEs rates 2	Grade ≥3 AEs rates 3	Grade ≥3 AEs rates 4	Grade ≥3 AEs rates 5=very differentiating
Dose discontinuation rates	Dose discontinuation rates 1=not at all differentiating	Dose discontinuation rates 2	Dose discontinuation rates 3	Dose discontinuation rates 4	Dose discontinuation rates 5=very differentiating
Median duration of treatment	Median duration of treatment 1=not at all differentiating	Median duration of treatment 2	Median duration of treatment 3	Median duration of treatment 4	Median duration of treatment 5=very differentiating
Rates of hematologic toxicities	Rates of hematologic toxicities 1=not at all differentiating	Rates of hematologic toxicities 2	Rates of hematologic toxicities 3	Rates of hematologic toxicities 4	Rates of hematologic toxicities 5=very differentiating
Rates of hematologic toxicities	Rates of hematologic toxicities 1=not at all differentiating	Rates of hematologic toxicities 2	Rates of hematologic toxicities 3	Rates of hematologic toxicities 4	Rates of hematologic toxicities 5=very differentiating
Rates of AESIs (ie, stomatitis, ILD, ocular events)	Rates of AESIs (ie, stomatitis, ILD, ocular events) 1=not at all differentiating	Rates of AESIs (ie, stomatitis, ILD, ocular events) 2	Rates of AESIs (ie, stomatitis, ILD, ocular events) 3	Rates of AESIs (ie, stomatitis, ILD, ocular events) 4	Rates of AESIs (ie, stomatitis, ILD, ocular events) 5=very differentiating

Other (please specify)

Question Title

* 5. Please think of the safety endpoints from TROPION-Breast01 collectively and rank in order of differentiation, where 1=least differentiating and 6=most differentiating

	1=not at all differentiating	2	3	4	5	6=most differentiating
Grade ≥3 AEs rates	Grade ≥3 AEs rates 1=not at all differentiating	Grade ≥3 AEs rates 2	Grade ≥3 AEs rates 3	Grade ≥3 AEs rates 4	Grade ≥3 AEs rates 5	Grade ≥3 AEs rates 6=most differentiating
Dose discontinuation rates	Dose discontinuation rates 1=not at all differentiating	Dose discontinuation rates 2	Dose discontinuation rates 3	Dose discontinuation rates 4	Dose discontinuation rates 5	Dose discontinuation rates 6=most differentiating
Median duration of treatment	Median duration of treatment 1=not at all differentiating	Median duration of treatment 2	Median duration of treatment 3	Median duration of treatment 4	Median duration of treatment 5	Median duration of treatment 6=most differentiating
Rates of hematologic toxicities	Rates of hematologic toxicities 1=not at all differentiating	Rates of hematologic toxicities 2	Rates of hematologic toxicities 3	Rates of hematologic toxicities 4	Rates of hematologic toxicities 5	Rates of hematologic toxicities 6=most differentiating
Rates of AESIs (ie, stomatitis, ILD, ocular events)	Rates of AESIs (ie, stomatitis, ILD, ocular events) 1=not at all differentiating	Rates of AESIs (ie, stomatitis, ILD, ocular events) 2	Rates of AESIs (ie, stomatitis, ILD, ocular events) 3	Rates of AESIs (ie, stomatitis, ILD, ocular events) 4	Rates of AESIs (ie, stomatitis, ILD, ocular events) 5	Rates of AESIs (ie, stomatitis, ILD, ocular events) 6=most differentiating
Other (please specify below)	Other (please specify below) 1=not at all differentiating	Other (please specify below) 2	Other (please specify below) 3	Other (please specify below) 4	Other (please specify below) 5	Other (please specify below) 6=most differentiating

Other (please specify)

Question Title

* 6. Please explain the rationale behind your top 3 choices for the most differentiating safety data from TROPION-Breast01 in the prior question.

Question Title

* 7. Based on the TROPION-Breast01 data, how likely would you be to incorporate Dato-DXd into your clinical practice for patients with post-ET, HR+/HER2− mBC?

Very unlikely

Unlikely

Neutral or unsure

Likely

Very likely

Question Title

* 8. Please explain the rationale behind your choice in the prior question.

Question Title

* 9. When assessing the role of Dato-DXd in the HR+/HER2− mBC treatment landscape and how it compares to other TROP2 ADCs, what are key differences between TROPION-Breast01 for Dato-DXd and TROPiCS-02 for sacituzumab govitecan?
Note that comparisons across trials should be discouraged, particularly when made without the context that trials have different designs and methodologies.

Datopotamab Deruxtecan (Dato-DXd) Global Commercial Breast Cancer Steering Committee Meeting
Premeeting Survey

Question Title

* Please enter the following information as you would like noted on the meeting materials:

Question Title

Question Title

* 2. Please think of the efficacy endpoints from TROPION-Breast01 collectively and rank in order of impact, where 1=least impactful and 8=most impactful.

Question Title

* 3. Please explain the rationale behind your top 3 choices for the most impactful efficacy data from TROPION-Breast01 in the prior question.

Question Title

* 4. For the safety data from TROPION-Breast01, please think of the following safety results individually and rate how well each result differentiates Dato-DXd in the HR+/HER2− mBC landscape, using a scale of 1 to 5, where 1=not at all differentiating and 5=very differentiating.

Question Title

* 5. Please think of the safety endpoints from TROPION-Breast01 collectively and rank in order of differentiation, where 1=least differentiating and 6=most differentiating

Question Title

* 6. Please explain the rationale behind your top 3 choices for the most differentiating safety data from TROPION-Breast01 in the prior question.

Question Title

* 7. Based on the TROPION-Breast01 data, how likely would you be to incorporate Dato-DXd into your clinical practice for patients with post-ET, HR+/HER2− mBC?

Question Title

* 8. Please explain the rationale behind your choice in the prior question.

Question Title

Question Title

* 10. How would you summarize the key takeaways from TROPION-Breast01 to a colleague?

Question Title

* 11. Which additional data not yet presented from TROPION-Breast01 are you most interested in seeing?

Question Title

* 12. What key data from ESMO 2023 and/or anticipated at SABCS 2023 do you believe will have the most impact on the post-ET HR+/HER2− mBC landscape?

Datopotamab Deruxtecan (Dato-DXd) Global Commercial Breast Cancer Steering Committee MeetingPremeeting Survey

Question Title

* Please enter the following information as you would like noted on the meeting materials:

Question Title

Question Title

* 2. Please think of the efficacy endpoints from TROPION-Breast01 collectively and rank in order of impact, where 1=least impactful and 8=most impactful.

Question Title

* 3. Please explain the rationale behind your top 3 choices for the most impactful efficacy data from TROPION-Breast01 in the prior question.

Question Title

* 4. For the safety data from TROPION-Breast01, please think of the following safety results individually and rate how well each result differentiates Dato-DXd in the HR+/HER2− mBC landscape, using a scale of 1 to 5, where 1=not at all differentiating and 5=very differentiating.

Question Title

* 5. Please think of the safety endpoints from TROPION-Breast01 collectively and rank in order of differentiation, where 1=least differentiating and 6=most differentiating

Question Title

* 6. Please explain the rationale behind your top 3 choices for the most differentiating safety data from TROPION-Breast01 in the prior question.

Question Title

* 7. Based on the TROPION-Breast01 data, how likely would you be to incorporate Dato-DXd into your clinical practice for patients with post-ET, HR+/HER2− mBC?

Question Title

* 8. Please explain the rationale behind your choice in the prior question.

Question Title

Question Title

* 10. How would you summarize the key takeaways from TROPION-Breast01 to a colleague?

Question Title

* 11. Which additional data not yet presented from TROPION-Breast01 are you most interested in seeing?

Question Title

* 12. What key data from ESMO 2023 and/or anticipated at SABCS 2023 do you believe will have the most impact on the post-ET HR+/HER2− mBC landscape?

Datopotamab Deruxtecan (Dato-DXd) Global Commercial Breast Cancer Steering Committee Meeting
Premeeting Survey